Another cost of generic Prilosec
Executive Summary
Andrx notes in Nov. 15 10-Q filing that scale-up for the expected launches of generic omeprazole and bupropion has affected production of commercial products. "Through much of 2002, besides the currently marketed products, the company was concurrently working toward building launch quantities for two significant potential product candidates, bioequivalent versions of Prilosec and Wellbutrin SR/Zyban, which resulted in inefficiencies, equipment failures and rejection lots, and at times interrupted the company's ability to fully meet the actual demand for certain of its products," Andrx said. Generic Prilosec launch supplies will not be used after a federal court ruled that Andrx infringed AstraZeneca's patents...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.